MEK or ERK inhibition effectively abrogates emergence of acquired osimertinib resistance in the treatment of EGFR-mutant lung cancers

BACKGROUND: The majority of non-small cell lung cancer (NSCLC) patients harboring activating EGFR mutations respond well to osimertinib (AZD9291), a third generation mutation-selective epidermal growth factor receptor (EGFR) inhibitor. The current study focuses on determining whether targeting MEK/E...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Cancer
Huvudupphovsmän: Gu, Jiajia, Yao, Weilong, Shi, Puyi, Zhang, Guojing, Owonikoko, Taofeek K., Ramalingam, Suresh S., Sun, Shi-Yong
Materialtyp: Artigo
Språk:Inglês
Publicerad: 2020
Ämnen:
Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC7381372/
https://ncbi.nlm.nih.gov/pubmed/32497272
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.32996
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk